Details for Patent: 11,202,778
✉ Email this page to a colleague
Which drugs does patent 11,202,778 protect, and when does it expire?
Patent 11,202,778 protects PHYRAGO and is included in one NDA.
This patent has six patent family members in six countries.
Summary for Patent: 11,202,778
| Title: | Amorphous solid dispersions of dasatinib and uses thereof |
| Abstract: | Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or infection. |
| Inventor(s): | Wertz Christian F., Chen Tzehaw |
| Assignee: | Nanocopoeia, LLC |
| Application Number: | US17206823 |
|
Patent Claim Types: see list of patent claims |
More… ↓ |
Drugs Protected by US Patent 11,202,778
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT | ⤷ Subscribe | ||||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT | ⤷ Subscribe | ||||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,202,778
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021210974 | ⤷ Subscribe | |||
| Canada | 3168667 | ⤷ Subscribe | |||
| European Patent Office | 4093379 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
